

of drafts of regulations or guidelines or similar preexisting internal agency documents, but only if their premature disclosure is likely to significantly frustrate implementation of proposed agency action; review of trade secrets and confidential commercial or financial information submitted to the agency; consideration of matters involving investigatory files compiled for law enforcement purposes; and review of matters, such as personnel records or individual patient records, where disclosure would constitute a clearly unwarranted invasion of personal privacy.

Examples of portions of FDA advisory committee meetings that ordinarily shall not be closed include the review, discussion, and evaluation of general preclinical and clinical test protocols and procedures for a class of drugs or devices; consideration of labeling requirements for a class of marketed drugs or devices; review of data and information on specific investigational or marketed drugs and devices that have previously been made public; presentation of any other data or information that is not exempt from public disclosure pursuant to the FACA, as amended; and, deliberation to formulate advice and recommendations to the agency on matters that do not independently justify closing.

This notice is issued under section 10(a)(1) and (2) of the Federal Advisory Committee Act (5 U.S.C. app. 2), and FDA's regulations (21 CFR part 14) on advisory committees.

Dated: March 9, 1995.

**Linda A. Suydam,**

*Interim Deputy Commissioner for Operations.*  
[FR Doc. 95-6427 Filed 3-15-95; 8:45 am]

BILLING CODE 4160-01-F

## Office of the Secretary

### Correction of Notice of Findings of Scientific Misconduct

**AGENCY:** Office of the Secretary, HHS.

**ACTION:** Correction.

**SUMMARY:** A Notice beginning on page 10588 in the issue of February 27, 1995, entitled "Findings of Scientific Misconduct" is hereby reprinted in its entirety because of an omission in the original printing:

*Vivian N. Tanner, Cleveland Clinic Foundation:* The Division of Research Investigations of the Office of Research Integrity (ORI) conducted an investigation into possible scientific misconduct on the part of Vivian N. Tanner while she was a clinic coordinator for the Collaborative Ocular

Melanoma Study (COMS) at the Cleveland Clinic Foundation (CCF). ORI concluded that Ms. Tanner committed scientific misconduct by falsifying and fabricating clinical trial data on research data forms related to a multicenter study on the treatment of choroidal melanoma, a rare form of eye cancer. Due to these falsifications and fabrications, inaccurate clinical data were entered into the clinical trial database. These acts were committed over a period of several years, were material, and, therefore, were potentially detrimental to the study. The CCF COMS project has received U.S. Public Health Service support from 1985 to the present through subcontract funds from a National Eye Institute cooperative agreement award to the COMS Coordinating Center, The Wilmer Ophthalmological Institute, The Johns Hopkins Medical Institutions, Baltimore, Maryland. Ms. Tanner has been debarred from eligibility for and involvement in grants as well as other assistance awards and contracts from the Federal Government for a period of three years. Because the COMS is an ongoing study, no publications were affected by the falsified or fabricated data, and no clinical treatment has been based on the results of the study.

**FOR FURTHER INFORMATION, CONTACT:** Director, Division of Research Investigations, Office of Research Integrity, 301-443-5330.

**Lyle W. Bivens, Ph.D.,**

*Director, Office of Research Integrity.*

[FR Doc. 95-6446 Filed 3-15-95; 8:45 am]

BILLING CODE 4160-17-P

## National Institutes of Health

### Division of Research Grants; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Division of Research Grants Special Emphasis Panel (SEP) meetings:

*Purpose/Agenda:* To review individual grant applications.

*Name of SEP:* Chemistry and Related Sciences.

*Date:* March 27, 1995.

*Time:* 2:00 p.m.

*Place:* NIH, Westwood Building, Room 320, Telephone Conference.

*Contact Person:* Dr. Zakir Bengali, Scientific Review Administrator, 5333 Westbard Ave., Room 320, Bethesda, MD 20892, (301) 594-7317.

*Name of SEP:* Microbiological and Immunological Sciences.

*Date:* April 3, 1995.

*Time:* 10:00 a.m.

*Place:* NIH, Westwood Building, Room 407B, Telephone Conference.

*Contact Person:* Dr. Betty Hayden, Scientific Review Administrator, 5333 Westbard Ave., Room 407B, Bethesda, MD 20892, (301) 594-7310.

*Name of SEP:* Microbiological and Immunological Sciences.

*Date:* April 3, 1995.

*Time:* 3:00 p.m.

*Place:* NIH, Westwood Building, Room 407B, Telephone Conference.

*Contact Person:* Dr. Betty Hayden, Scientific Review Administrator, 5333 Westbard Ave., Room 407B, Bethesda, MD 20892, (301) 594-7310.

*Name of SEP:* Behavioral and Neurosciences.

*Date:* April 3, 1995.

*Time:* 8:30 a.m.

*Place:* Holiday Inn, Chevy Chase, MD.

*Contact Person:* Dr. Teresa Levitin, Scientific Review Admin., 5333 Westbard Ave., Room 303, Bethesda, MD 20894, (301) 594-7141.

*Name of SEP:* Chemistry and Related Sciences.

*Date:* April 4, 1995.

*Time:* 1:00 p.m.

*Place:* NIH, Westwood Building, Room 435, Telephone Conference.

*Contact Person:* Dr. Marcelina Powers, Scientific Review Administrator, 5333 Westbard Ave., Room 435, Bethesda, MD 20892, (301) 594-7120.

*Name of SEP:* Microbiological and Immunological Sciences.

*Date:* April 4, 1995.

*Time:* 3:00 p.m.

*Place:* NIH, Westwood Building, Room 407B, Telephone Conference.

*Contact Person:* Dr. Betty Hayden, Scientific Review Administrator, 5333 Westbard Ave., Room 407B, Bethesda, MD 20892, (301) 594-7310.

*Name of SEP:* Chemistry and Related Sciences.

*Date:* April 6, 1995.

*Time:* 1:30 p.m.

*Place:* NIH, Westwood Building, Room 339B, Telephone Conference.

*Contact Person:* Dr. Jerry Critz, Scientific Review Administrator, 5333 Westbard Ave., Room 339B, Bethesda, MD 20892, (301) 594-7322.

*Name of SEP:* Microbiological and Immunological Sciences.

*Date:* April 7, 1995.

*Time:* 1:00 p.m.

*Place:* NIH, Westwood Building, Room 403C, Telephone Conference.

*Contact Person:* Dr. Anita Weinblatt, Scientific Review Admin., 5333 Westbard Ave., Room 403C, Bethesda, MD 20892, (301) 594-7175.

*Name of SEP:* Chemistry and Related Sciences.

*Date:* April 12, 1995.

*Time:* 1:00 p.m.

*Place:* NIH, Westwood Building, Room 435, Telephone Conference.

*Contact Person:* Dr. Marcelina Powers, Scientific Review Administrator, 5333 Westbard Ave., Room 435, Bethesda, MD 20892, (301) 594-7120.